Page last updated: 2024-11-07

metaraminol and Brugada Syndrome

metaraminol has been researched along with Brugada Syndrome in 1 studies

Metaraminol: A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.
metaraminol : A member of the class of phenylethanolamines that is 2-amino-1-phenylethanol substituted by a methyl group at position 2 and a phenolic hydroxy group at position 1. A sympathomimetic agent , it is used in the treatment of hypotension.

Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
VICK, RL1

Other Studies

1 other study available for metaraminol and Brugada Syndrome

ArticleYear
EFFECTS OF INCREASED TRANSMURAL PRESSURES UPON ATRIAL AND VENTRICULAR RHYTHMS IN THE DOG HEART-LUNG PREPARATION.
    Circulation research, 1963, Volume: 13

    Topics: Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Dogs; Epinephrine; Heart

1963